|By PR Newswire||
|March 31, 2014 07:02 PM EDT||
DUBLIN, April 1, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/c3vlm5/global) has announced the addition of the "Global Radiopharmaceuticals Market Insight" report to their offering.
Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics.
In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly.
A major part of the radiopharmaceuticals market is dominated by diagnostic radiopharmaceuticals, where, SPECT and PET isotopes are most common. The new innovations in nuclear medicine to target coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future.
The other segment of the market is the therapeutic segment, which accounts for the remaining 10%. This segment is mainly dominated by isotopes like I-131, Sm-153, Re-186, Y-90, and Lu-177. It is expected that over the next 5-6 years horizon, this market would witness a steep increase owing to the introduction of many new products for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers.
The increasing popularity and use of SPECT and PET scans, new and efficient technological equipment, increased awareness about radiopharmaceuticals among physicians and most importantly, the easy availability of radiopharmaceutical from cyclotrons are some of the major factors driving the global radiopharmaceutical market.
Inspite of the market for radiopharmaceuticals growing rapidly, there are many challenges, like high cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals. Additionally, there are also some obstacles with regards to the manufacturing of radioisotopes, which need to be addressed to tap the opportunities.
The global market for radiopharmaceuticals was estimated to be valued at approximately USD 5.3 billion in 2013. Owing to factors like the increasing adoption rates of PET and SPECT scanners, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons, coupled with significant developments in research and technology, this market is expected to record a CAGR of close to 15% to reach approximately USD 10.6 billion by 2018.
Key Topics Covered:
1. Global Radiopharmaceuticals Market Outlook
2. Europe Guidelines for Radiopharmaceuticals
3. US Guidelines for Radiopharmaceuticals
4. Canada Guidelines for Radiopharmaceuticals
5. Radiopharmaceuticals Clinical Trial Insight by Indication, Country & Phase
6. Marketed Radiopharmaceuticals by Indication & Country
7. Discontinued & Suspended Radiopharmaceuticals Drug Profiles by Indication, Country & Phase
8. Competitive Landscape
- AREVA Med
- Actinium Pharmaceuticals
- Avid Radiopharmaceuticals
- Bayer HealthCare Pharmaceuticals
- Cardinal Health
- GE Healthcare
- Ion Beam Applications
- Lantheus Medical Imaging
- Lantheus Medical Imaging
- Merck & Co
- PETNET Solutions (Siemens Healthcare Global)
For more information visit http://www.researchandmarkets.com/research/c3vlm5/global
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
In his session at @ThingsExpo, Kausik Sridharabalan, founder and CTO of Pulzze Systems, Inc., will focus on key challenges in building an Internet of Things solution infrastructure. He will shed light on efficient ways of defining interactions within IoT solutions, leading to cost and time reduction. He will also introduce ways to handle data and how one can develop IoT solutions that are lean, flexible and configurable, thus making IoT infrastructure agile and scalable.
Sep. 28, 2016 08:30 AM EDT Reads: 1,565
Technology vendors and analysts are eager to paint a rosy picture of how wonderful IoT is and why your deployment will be great with the use of their products and services. While it is easy to showcase successful IoT solutions, identifying IoT systems that missed the mark or failed can often provide more in the way of key lessons learned. In his session at @ThingsExpo, Peter Vanderminden, Principal Industry Analyst for IoT & Digital Supply Chain to Flatiron Strategies, will focus on how IoT de...
Sep. 28, 2016 08:30 AM EDT Reads: 1,149
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
Sep. 28, 2016 08:15 AM EDT Reads: 534
"We have several customers now running private clouds. They're not as large as they should be but it's getting there. The adoption challenge has been pretty simple. Look at the world today of virtualization vs cloud," stated Nara Rajagopalan, CEO of Accelerite, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Sep. 28, 2016 08:00 AM EDT Reads: 2,410
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, will discuss recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model f...
Sep. 28, 2016 08:00 AM EDT Reads: 2,050
Sep. 28, 2016 07:45 AM EDT Reads: 2,243
Sep. 28, 2016 07:45 AM EDT Reads: 2,257
Sep. 28, 2016 07:30 AM EDT Reads: 2,875
Sep. 28, 2016 07:30 AM EDT Reads: 2,902
Sep. 28, 2016 07:00 AM EDT Reads: 2,685
Sep. 28, 2016 07:00 AM EDT Reads: 3,461
Sep. 28, 2016 07:00 AM EDT Reads: 2,879
Sep. 28, 2016 07:00 AM EDT Reads: 3,359
Sep. 28, 2016 07:00 AM EDT Reads: 2,090
Sep. 28, 2016 07:00 AM EDT Reads: 2,239